Details der Publikation - Vaccination for Recovered Inpatients with COVID-19 (VATICO)

Vaccination for Recovered Inpatients with COVID-19 (VATICO) : SARS-CoV-2 vaccination strategies in previous hospitalised and recovered COVID-19 patients - VATICO

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 13. Sept. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still [TICO assignment] blinded, and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups of the Moderna mRNA 1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines) MedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 100000004865;Therapeutic area: Health Care [N] - Environment and Public Health [N06] Phase: Phase 4 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-07-2021, Last updated: 2022-11-24

ICTRP ID:	EUCTR2021-003386-35-ES INSIGHT-016

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO007904649

Internformat


LEADER	01000caa a22002652 4500
001	WHO007904649
003	DE-627
005	20230425172552.0
007	cr uuu---uuuuu
008	210922s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO007904649
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2021-003386-35-ES
035			\|a (UBBS_Klinische_Studien_WHO)INSIGHT-016
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Vaccination for Recovered Inpatients with COVID-19 (VATICO) \|b SARS-CoV-2 vaccination strategies in previous hospitalised and recovered COVID-19 patients - VATICO
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-07-2021, Last updated: 2022-11-24
650		4	\|a Medical Condition: Participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still [TICO assignment] blinded, and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups of the Moderna mRNA 1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines) MedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 100000004865;Therapeutic area: Health Care [N] - Environment and Public Health [N06]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 4
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 13. Sept.
773	1	8	\|g year:2021 \|g day:13 \|g month:09
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-003386-35 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 13 \|c 09

Vaccination for Recovered Inpatients with COVID-19 (VATICO) : SARS-CoV-2 vaccination strategies in previous hospitalised and recovered COVID-19 patients - VATICO

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände